Tema Oncology ETF
CANC
12 hedge funds and large institutions have $23.5M invested in Tema Oncology ETF in 2026 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 0 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
100% more funds holding
Funds holding: 6 → 12 (+6)
34.24% less ownership
Funds ownership: 48.23% → 13.99% (-34%)
57% less capital invested
Capital invested by funds: $54.6M → $23.5M (-$31.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPL Financial
San Diego,
California
|
+$3.43M |
| 2 |
WF
Willow Financial
Rogers,
Arkansas
|
+$2.52M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$2.52M |
| 4 |
Jane Street
New York
|
+$2.07M |
| 5 |
HighTower Advisors
Chicago,
Illinois
|
+$1.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
-$47.9M |
CANC Hedge Fund Activity: Q1 2026 in Review
12 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in Tema Oncology ETF (CANC) for Q1 2026, worth a combined $23.5M — down 57% from $54.6M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new CANC positions and 0 closed out — a net gain of 6 holders — while 3 added to existing stakes and 1 trimmed.
The largest buyer was LPL Financial, adding an estimated $3.43M. The largest seller was Thrivent Financial for Lutherans, cutting an estimated $47.9M.
- 12 institutional investors held Tema Oncology ETF (CANC) as of Q1 2026, up from 6 in Q4 2025.
- Funds reported $23.5M of Tema Oncology ETF stock for Q1 2026, down 57% quarter-over-quarter.
- 6 funds opened new Tema Oncology ETF positions in Q1 2026 and 0 closed out, a net change of +6 holders.
- The largest Tema Oncology ETF buyer in Q1 2026 was LPL Financial, an estimated $3.43M added.
- The largest Tema Oncology ETF seller in Q1 2026 was Thrivent Financial for Lutherans, an estimated $47.9M sold.
Based on aggregated 13F filings for Q1 2026.